Cybin Inc.
Cybin Inc. (CYBN) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
cybn · pe ratio · data through Jun 9, 2026
Core PE Ratio Metrics
Trailing 12 months · TTMInsufficient PE history data (fewer than 3 valid fiscal years).
PE Ratio vs Peers
Biotechnology · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
Cybin Inc.You CYBN | $413M | N/A | — | -$2.93 |
 Alector, Inc. ALEC | $186M | N/A | — | -$1.39 |
 Insight Molecular Diagnostics Inc. IMDX | $161M | N/A | — | -$1.65 |
 Innate Pharma S.A. IPHA | $165M | N/A | — | -$0.55 |
 Milestone Pharmaceuticals Inc. MIST | $106M | N/A | — | -$0.75 |
 Molecular Partners AG MOLN | $143M | N/A | — | -$1.65 |
 Nkarta, Inc. NKTX | $176M | N/A | — | -$1.41 |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for Cybin Inc. (CYBN) measures how much investors pay for each dollar of the company's trailing earnings. CYBN's current PE ratio of N/A is calculated by dividing its stock price of $8.28 by its TTM earnings per share of -$2.93.
Frequently asked questions
CYBN pe ratio · 6 questionsCYBN's current PE ratio is N/A as of 2026-06-09, based on a stock price of $8.28 and TTM EPS of -$2.93. Data sourced from Financial Modeling Prep via CYBN's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Cybin Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-09